Abstract:Asthma is one of the most common noncommunicable diseases, affecting over 200 million people. A large number of drugs control asthma attacks, but there is no effective therapy. Identification of reasons for asthma and preventing this disease is a relevant task. The influence of bacterial components is necessary for the normal development of the immune system and the formation of an adequate immune response to antigens. In the absence of microorganisms or their insufficient exposure, the prerequisites are formed for excessive reactivity to harmless antigens. In the present study, we analyzed cellular and humoral factors in a standard mouse model of OVA-induced asthma modified by 5-fold intraperitoneal injection of bacterial cell wall fragments of glucosaminylmuramyl dipeptide (GMDP) 5 μg/animal or 1 μg lipopolysaccharide (LPS) per animal for 5 days before sensitization by ovalbumin (OVA). Preliminary administration of LPS or GMDP to animals significantly reduced goblet cells as well as the number of neutrophils, lymphocytes, and eosinophils in bronchoalveolar lavage, wherein GMDP corrected neutrophilia to a 2-fold degree, and LPS reduced the severity of eosinophilia by 1.9 times. With OVA administration of GMDP or LPS at the sensitization stage, an increase in the total number of bronchoalveolar lavage cells due to neutrophils, macrophages, lymphocytes, and eosinophils in relation to the group with asthma without GMDP or LPS was observed. The administration of GMDP or LPS to normal mice without asthma for 5 days had no statistically significant effect on the change in the number and population composition of cells in bronchoalveolar lavage in comparison with the control group receiving PBS. As a result of a study in a mouse model of asthma, a dual effect of LPS and GMDP was established: the introduction of LPS or GMDP before sensitization reduces neutrophilia and eosinophilia, while the introduction of LPS or GMDP together with an allergen significantly increases neutrophilia and eosinophilia. The study of the immunoglobulin status shows that in normal-asthma mice, GMDP and LPS slightly increase IgA in bronchoalveolar lavage; at the same time, in the asthma model, injections of GMDP or LPS before sensitization contribute to a significant decrease in IgA (2.6 times and 2.1 times, respectively) in BALF and IgE (2.2 times and 2.0 times, respectively) in blood serum. In an experimental model of asthma, the effect of GMDP and LPS was multidirectional: when they are repeatedly administered before sensitization, the bacterial components significantly reduce the severity of the allergic process, while in the case of a joint injection with an allergen, they increase the influx of macrophages, lymphocytes, and neutrophils into the lungs, which can aggravate the course of pathological process. Thus, the insufficient effect of antigens of a bacterial nature, in particular, with prolonged use of antibiotics can be compensated for by substances based on low-molecular-weight bioregulators of bacterial origin to establish the missing signals for innate immunity receptors, whose constant activation at a certain level is necessary to maintain homeostasis.

Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice

Generation of IgE-specific Cytotoxic T Lymphocytes As a Novel Immunotherapeutic Approach for the Treatment of Allergic Asthma.

Altered Frequency of NK Cells and Treg Cells by <i>Astragalus</i> Polysaccharide Combined with Budesonide in Asthma Model Mice

Antibodies Specific for a Segment of Human Membrane IgE Deplete IgE-producing B Cells in Humanized Mice.

Interleukin-13 Peptide Kinoid Vaccination Attenuates Allergic Inflammation In A Mouse Model Of Asthma

Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice.

Interleukin-2 family cytokines IL-9 and IL-21 differentially regulate innate and adaptive type 2 immunity in asthma

Depletion of Major Pathogenic Cells in Asthma by Targeting CRTh2

Reduction of Serum IgE by Depletion of the IgE B Cell Lineage - a Novel Approach for the Treatment of Allergic Diseases (140.7)

The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

Neutralization of either IL-17A or IL-17F is sufficient to inhibit house dust mite induced allergic asthma in mice.

Control of Allergic Reactions in Mice by an Active Anti-Murine IL-4 Immunization

Lung Dysfunction in a Mouse Model of Inflammation is Dependent on T-cell-independent IL-13 Expression (54.18)

Interleukin-17 Orchestrates the Granulocyte Influx into Airways after Allergen Inhalation in A Mouse Model of Allergic Asthma

Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma1

A therapeutic strategy to target distinct sources of IgE and durably reverse allergy

Immunosuppression In Early Postnatal Days Induces Persistent And Allergen-Specific Immune Tolerance To Asthma In Adult Mice

A New Immunotherapy Approach: Mucosal Immunization with an Il-13 Vaccine Suppresses Murine Airway Allergic Responses

Dual Effect of Low-Molecular-Weight Bioregulators of Bacterial Origin in Experimental Model of Asthma

Effects of anti-IgE antibody on airway resistance and levels of Th2 cytokines in asthmatic mouse and its mechanisms

Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma